NCT04802759 2026-04-13
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
Hoffmann-La Roche
Phase 1/2 Recruiting
Clinical Trials
13 trialsNCT05095207 2026-04-13
Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer
Icahn School of Medicine at Mount Sinai
Phase 1/2 Recruiting
NCT05113537 2026-04-13
UPLIFT
University of California, San Francisco
Phase 1/2 Recruiting
NCT06498648 2026-04-13
Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
National Cancer Institute (NCI)
Phase 1/2 Recruiting
NCT06810544 2026-04-13
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Tango Therapeutics, Inc.
Phase 1/2 Recruiting
NCT06835972 2026-04-09
A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)
Memorial Sloan Kettering Cancer Center
Phase 1/2 Recruiting
NCT06188520 2026-04-08
CYCAD-1
AstraZeneca
Phase 1/2 Recruiting
NCT05386108 2026-04-06
ELECTRA
Stemline Therapeutics, Inc.
Phase 1/2 Recruiting
NCT04486352 2026-04-01
EndoMAP
Alliance Foundation Trials, LLC.
Phase 1/2 Recruiting
NCT04750928 2026-04-01
Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT05735080 2026-04-01
INX-315-01
Incyclix Bio
Phase 1/2 Recruiting
NCT04791384 2026-03-31
Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer
Criterium, Inc.
Phase 1/2 Terminated
NCT05573126 2026-03-20
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
Ellipses Pharma
Phase 1/2 Recruiting